Skip to content

Diabetes Mellitus Type 2 And Homoeopathy

Role Of Individualized Homoeopathic Medicine In The Treatment of Diabetes Mellitus Type 2: An Open Label, Single Arm, Study In Adults - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/11/097632
Enrollment
70
Registered
2025-11-18
Start date
Unknown
Completion date
Unknown
Last updated
2025-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E11- Type 2 diabetes mellitus

Interventions

Intervention1: Individualized Homoeopathic Medicine: Intervention is planned by administering the most indicated homoeopathic medicines in any potency. The content of each dose is one cane sugar globu
dosage and repetition depends upon the requirement of individual cases. Patients will be given the advice to avoid eating, drinking, brushing the teeth or smoking within 30 minutes of taking the globu

Sponsors

Dr Rajdeep Lahiri
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Age group patients of age 18-60 years 2.Patients of both sexes 3.Patients with HbA1c levels more than 7.0 percent 4.Patients with pre-diagnosed diabetes mellitus type2 5.Patients with FBS more than 140 mg per dL and PPBS more than 200 mg per dL 6.Patients who are not taking any anti-diabetic treatment for a minimum of 3 months from any system of medicine 7.Patient who is interested to take treatment on a regular basis with timely follow up can provide valid consent to participate in the study

Exclusion criteria

Exclusion criteria: 1.Patients suffering from other comorbid conditions like chronic tuberculosis, cancer, chronic kidney disease in addition to type 2 diabetes mellitus 2.Pregnant women with lactating mothers 3.Chronic liver disease patients 4.All other types of diabetes mellitus will be excluded 5.Other major systemic illness

Design outcomes

Primary

MeasureTime frame
HbA1c-6 to 7 Good control HbA1C-7-8 Moderate control HbA1C- Above 8 Poor control Timepoint: 3 Months

Secondary

MeasureTime frame
1.It is expected that changes will be seen in QoL scale. Will be assessed at the baseline and at the completion of 3 months 2.It is expected that there will be reduction in FBS and PPBS levels after 3 months. Timepoint: 3 Months

Countries

India

Contacts

Public ContactDr Himangsu Hait

The Calcutta Homoeopathic Medical College and Hospital

haitdrhimangsu@gmail.com9433565680

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026